Toll Free (US/Canada): 1-888-778-7886
Report Code: LS10755
Category : Pharmaceuticals
The global antibody drug conjugates (ADCs) therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.
The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.
ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.
A large number of pharmaceutical companies are focusing towards research and development of ADCs. However, certain factors such as unknown etiology, complex pathophysiology and high treatment cost of cancer are expected to hamper the growth of the global market during the forecast period.
Geographically, North America is expected to be the largest market for ADCs, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of cancer. The U.S. contributed largest revenue to the North American ADCs market and it is expected to remain the largest market globally, during the forecast period.
Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.
Select License Type